Comprehensive Stock Comparison
Compare AMN Healthcare Services, Inc. (AMN) vs Cryo-Cell International, Inc. (CCEL) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | CCEL | 2.0% revenue growth vs AMN's -21.3% |
| Value | AMN | Lower P/E (9.6x vs 67.4x) |
| Quality / Margins | CCEL | 1.3% net margin vs AMN's -3.5% |
| Stability / Safety | CCEL | Beta 0.16 vs AMN's 1.00 |
| Dividends | CCEL | 7.3% yield; AMN pays no meaningful dividend |
| Momentum (1Y) | AMN | -23.1% vs CCEL's -55.4% |
| Efficiency (ROA) | CCEL | 0.6% ROA vs AMN's -4.6% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
AMN Healthcare is a leading healthcare staffing and workforce solutions company that connects healthcare facilities with temporary and permanent medical professionals. It generates revenue primarily through staffing services—with nurse and allied staffing making up the largest segment—alongside physician placement and technology-enabled workforce management solutions. The company's scale, extensive network of healthcare professionals, and established relationships with thousands of healthcare facilities create significant barriers to entry for competitors.
Cryo-Cell International is a cellular processing and cryogenic storage company that preserves umbilical cord blood and tissue stem cells for family use. It generates revenue primarily from cord blood and cord tissue storage services—charging initial processing fees and annual storage fees—with additional income from selling its PrepaCyte CB processing technology to other storage facilities. The company's competitive advantage lies in its established reputation in the family cord blood banking market, proprietary processing technology, and direct-to-consumer marketing relationships with healthcare providers.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
CCEL leads in 3 of 6 categories (Financial Metrics, Profitability & Efficiency). AMN leads in 1 (Valuation Metrics). 1 tied.
Financial Metrics (TTM)
AMN is the larger business by revenue, generating $2.7B annually — 86.0x CCEL's $32M. Profitability is closely matched — net margins range from 1.3% (CCEL) to -3.5% (AMN). On growth, AMN holds the edge at +1.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | AMNAMN Healthcare Se… | CCELCryo-Cell Interna… |
|---|---|---|
| RevenueTrailing 12 months | $2.7B | $32M |
| EBITDAEarnings before interest/tax | $25M | $6M |
| Net IncomeAfter-tax profit | -$96M | $399,609 |
| Free Cash FlowCash after capex | $242M | $6M |
| Gross MarginGross profit ÷ Revenue | +28.3% | +77.1% |
| Operating MarginEBIT ÷ Revenue | -2.0% | +13.6% |
| Net MarginNet income ÷ Revenue | -3.5% | +1.3% |
| FCF MarginFCF ÷ Revenue | +8.9% | +19.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +1.8% | -3.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +95.9% | -30.8% |
Valuation Metrics
On an enterprise value basis, CCEL's 10.0x EV/EBITDA is more attractive than AMN's 29.2x.
| Metric | AMNAMN Healthcare Se… | CCELCryo-Cell Interna… |
|---|---|---|
| Market CapShares × price | $987M | $27M |
| Enterprise ValueMkt cap + debt − cash | $2.1B | $40M |
| Trailing P/EPrice ÷ TTM EPS | -5.06x | 67.40x |
| Forward P/EPrice ÷ next-FY EPS est. | 9.57x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 29.18x | 9.97x |
| Price / SalesMarket cap ÷ Revenue | 0.33x | 0.85x |
| Price / BookPrice ÷ Book value/share | 1.05x | — |
| Price / FCFMarket cap ÷ FCF | 4.12x | 7.53x |
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), CCEL scores 7/9 vs AMN's 4/9, reflecting strong financial health.
| Metric | AMNAMN Healthcare Se… | CCELCryo-Cell Interna… |
|---|---|---|
| ROE (TTM)Return on equity | -14.9% | — |
| ROA (TTM)Return on assets | -4.6% | +0.6% |
| ROICReturn on invested capital | -3.9% | — |
| ROCEReturn on capital employed | -5.0% | +8.3% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 7 |
| Debt / EquityFinancial leverage | 1.55x | — |
| Net DebtTotal debt minus cash | $1.1B | $12M |
| Cash & Equiv.Liquid assets | $11M | $560,960 |
| Total DebtShort + long-term debt | $1.1B | $13M |
| Interest CoverageEBIT ÷ Interest expense | -1.39x | 1.62x |
Total Returns (with DRIP)
A $10,000 investment in CCEL five years ago would be worth $5,120 today (with dividends reinvested), compared to $2,553 for AMN. Over the past 12 months, AMN leads with a -23.1% total return vs CCEL's -55.4%. The 3-year compound annual growth rate (CAGR) favors CCEL at 1.7% vs AMN's -40.0% — a key indicator of consistent wealth creation.
| Metric | AMNAMN Healthcare Se… | CCELCryo-Cell Interna… |
|---|---|---|
| YTD ReturnYear-to-date | +28.8% | -1.7% |
| 1-Year ReturnPast 12 months | -23.1% | -55.4% |
| 3-Year ReturnCumulative with dividends | -78.4% | +5.2% |
| 5-Year ReturnCumulative with dividends | -74.5% | -48.8% |
| 10-Year ReturnCumulative with dividends | -31.5% | +31.2% |
| CAGR (3Y)Annualised 3-year return | -40.0% | +1.7% |
Risk & Volatility
CCEL is the less volatile stock with a 0.16 beta — it tends to amplify market swings less than AMN's 1.00 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AMN currently trades 71.7% from its 52-week high vs CCEL's 42.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | AMNAMN Healthcare Se… | CCELCryo-Cell Interna… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.00x | 0.16x |
| 52-Week HighHighest price in past year | $27.17 | $7.91 |
| 52-Week LowLowest price in past year | $14.87 | $3.10 |
| % of 52W HighCurrent price vs 52-week peak | +71.7% | +42.6% |
| RSI (14)Momentum oscillator 0–100 | 50.8 | 49.7 |
| Avg Volume (50D)Average daily shares traded | 1.1M | 13K |
Analyst Outlook
CCEL is the only dividend payer here at 7.30% yield — a key consideration for income-focused portfolios.
| Metric | AMNAMN Healthcare Se… | CCELCryo-Cell Interna… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — |
| Price TargetConsensus 12-month target | $22.88 | — |
| # AnalystsCovering analysts | 17 | — |
| Dividend YieldAnnual dividend ÷ price | — | +7.3% |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | $0.25 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +5.2% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| AMN Healthcare Serv… (AMN) | 100 | 29.18 | -70.8% |
| Cryo-Cell Internati… (CCEL) | 100 | 47.14 | -52.9% |
Cryo-Cell Internati… (CCEL) returned -49% over 5 years vs AMN Healthcare Serv… (AMN)'s -74%.
Chart 2Revenue Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| AMN Healthcare Serv… (AMN) | $1.5B | $3.0B | +103.9% |
| Cryo-Cell Internati… (CCEL) | $21M | $32M | +51.7% |
AMN Healthcare Services, Inc.'s revenue grew from $1.5B (2015) to $3.0B (2024) — a 8.2% CAGR. Cryo-Cell International, Inc.'s revenue grew from $21M (2015) to $32M (2024) — a 4.7% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| AMN Healthcare Serv… (AMN) | 5.6% | -4.9% | -188.0% |
| Cryo-Cell Internati… (CCEL) | 38.4% | 1.3% | -96.7% |
AMN Healthcare Services, Inc.'s net margin went from 6% (2015) to -5% (2024). Cryo-Cell International, Inc.'s net margin went from 38% (2015) to 1% (2024).
Chart 4P/E Ratio History — 8 Years
| Stock | 2017 | 2024 | Change |
|---|---|---|---|
| AMN Healthcare Serv… (AMN) | 18.4 | 14 | -23.9% |
| Cryo-Cell Internati… (CCEL) | 32.2 | 148.2 | +360.2% |
AMN Healthcare Services, Inc. has traded in a 10x–46x P/E range over 7 years; current trailing P/E is ~-5x. Cryo-Cell International, Inc. has traded in a 13x–148x P/E range over 6 years; current trailing P/E is ~67x.
Chart 5EPS Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| AMN Healthcare Serv… (AMN) | 1.68 | -3.85 | -329.2% |
| Cryo-Cell Internati… (CCEL) | 0.83 | 0.05 | -94.0% |
AMN Healthcare Services, Inc.'s EPS grew from $1.68 (2015) to $-3.85 (2024) — a NaN% CAGR. Cryo-Cell International, Inc.'s EPS grew from $0.83 (2015) to $0.05 (2024) — a -27% CAGR.
Chart 6Free Cash Flow — 5 Years
AMN Healthcare Services, Inc. generated $240M FCF in 2024 (-5% vs 2021). Cryo-Cell International, Inc. generated $4M FCF in 2024 (+270% vs 2021).
AMN vs CCEL: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is AMN or CCEL a better buy right now?
Cryo-Cell International, Inc. (CCEL) offers the better valuation at 67.4x trailing P/E, making it the more compelling value choice. Analysts rate AMN Healthcare Services, Inc. (AMN) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — AMN or CCEL?
Over the past 5 years, Cryo-Cell International, Inc. (CCEL) delivered a total return of -48.8%, compared to -74.5% for AMN Healthcare Services, Inc. (AMN). A $10,000 investment in CCEL five years ago would be worth approximately $5K today (assuming dividends reinvested). Over 10 years, the gap is even starker: CCEL returned +31.2% versus AMN's -31.5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — AMN or CCEL?
By beta (market sensitivity over 5 years), Cryo-Cell International, Inc. (CCEL) is the lower-risk stock at 0.16β versus AMN Healthcare Services, Inc.'s 1.00β — meaning AMN is approximately 509% more volatile than CCEL relative to the S&P 500.
04Which has better profit margins — AMN or CCEL?
Cryo-Cell International, Inc. (CCEL) is the more profitable company, earning 1.3% net margin versus -4.9% for AMN Healthcare Services, Inc. — meaning it keeps 1.3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CCEL leads at 10.9% versus -3.4% for AMN. At the gross margin level — before operating expenses — CCEL leads at 75.2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — AMN or CCEL?
In this comparison, CCEL (7.3% yield) pays a dividend. AMN does not pay a meaningful dividend and should not be held primarily for income.
06Is AMN or CCEL better for a retirement portfolio?
For long-horizon retirement investors, Cryo-Cell International, Inc. (CCEL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.16), 7.3% yield). Both have compounded well over 10 years (CCEL: +31.2%, AMN: -31.5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between AMN and CCEL?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: AMN is a small-cap quality compounder stock; CCEL is a small-cap income-oriented stock. CCEL pays a dividend while AMN does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.